Article

Initial Analysis of Viral Dynamics and Circulating Viral Variants During the mRNA-1273 Phase 3 COVE Trial

2021-09-29

Abstract excerpt

This analysis assessed the impact of mRNA-1273 vaccination on the viral dynamics of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the ongoing Coronavirus Efficacy (COVE) trial. mRNA-1273 vaccination significantly reduced SARS-CoV-2 viral copy number (95% confidence interval [CI]) by 100-fold on the day of diagnosis (4.1 [3.4-4.8] versus placebo (6.2 [6.0-6.4] log10 copies/ml). Median ti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9750bb34-f7b0-5a39-83cb-06d2a8cadc9d
DOI: 10.1101/2021.09.28.21264252

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Initial Analysis of Viral Dynamics and Circulating Viral Variants During the mRNA-1273 Phase 3 COVE TrialDOI 10.1101/2021.09.28.21264252Read

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisSemantic proximity Read

Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort StudySemantic proximity Read

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infectionSemantic proximity Read

Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.SSemantic proximity Read

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE TrialSemantic proximity Read

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read

Durability of Responses after SARS-CoV-2 mRNA-1273 VaccinationSemantic proximity Read

Comparison of Two Highly-Effective mRNA Vaccines for COVID-19 During Periods of Alpha and Delta Variant PrevalenceSemantic proximity Read

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine BoosterSemantic proximity Read

Serum Neutralizing Activity of mRNA-1273 Against the SARS-CoV-2 B.1.1.529 (Omicron) Variant: A Preliminary ReportSemantic proximity Read

Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care settingSemantic proximity Read

Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalenceSemantic proximity Read